Oral Caffeine Use for Pain Management in AIS Patients After Spinal Fusion
Primary Purpose
Adolescent Idiopathic Scoliosis
Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Caffeine Tablet
Placebo
Sponsored by
About this trial
This is an interventional supportive care trial for Adolescent Idiopathic Scoliosis
Eligibility Criteria
Inclusion Criteria:
- must meet criteria for surgical correction of scoliosis
- must be able to swallow pills
- must have English as a primary language
- must possess mental capacity to understand purpose of the study
- patient must carry diagnosis of adolescent idiopathic scoliosis
- surgery must be performed via posterior approach
- operation performed by either Dr. John T. Anderson or Dr. Richard M. Schwend
- post-surgical AIS patients from June 2019-June 2024
- the patient must be between the ages of 12 and 17 years old
- the patient and one of their biological parents or guardian(s) must give consent for patient to be included in this study
Exclusion Criteria:
- obesity, as defined by a BMI at or above the 95th percentile
- weight below 40 kg
- any orthopedic diagnosis other than AIS
- revision spine surgery
- anterior or combined approach
- admission to PICU post-op
- use of Oxycodone post-op
- allergies to ibuprofen, caffeine, codeine, or diazepam
- history of renal disease
- history of a coagulation disorder
- history of cardiac dysrhythmia or open heart surgery
- history of Chronic Pain Syndrome or Complex Regional Pain Syndrome
- current use of oral central nervous system stimulant (e.g. methylphenidate)
Sites / Locations
- Children'S Mercy Hospitals & ClinicRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Caffeine arm
Placebo arm
Arm Description
Experimental Group: patient group (n = 34) receiving a 100 mg dose of caffeine (1/2 of a 200mg tablet to be taken whole or crushed), taken twice daily. This will be an adjuvant to their standard pain control.
Control group: patient group (n = 34) receiving placebo compounded to look similar to the caffeine treatment, taken twice daily. This will be an adjuvant to their standard pain control.
Outcomes
Primary Outcome Measures
Total number of demands for oral opioids from transition off PCA until discharge from hospital
Documented opioid use
Secondary Outcome Measures
Verbal analog pain scale ratings
Utilizing Verbal Analog Scale 0-10, 0 being no pain and 10 being severe pain
Average heart rate during hospital stay
Documented heart rates which are then averaged over 24 hours
Average systolic blood pressure during hospital stay
Documented systolic blood pressures which are then averaged over 24 hours
Full Information
NCT ID
NCT04950660
First Posted
June 15, 2021
Last Updated
September 5, 2023
Sponsor
Children's Mercy Hospital Kansas City
1. Study Identification
Unique Protocol Identification Number
NCT04950660
Brief Title
Oral Caffeine Use for Pain Management in AIS Patients After Spinal Fusion
Official Title
Oral Caffeine Decreases the Frequency of Opioid Demand in AIS Patients After Spinal Fusion
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 11, 2019 (Actual)
Primary Completion Date
November 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Children's Mercy Hospital Kansas City
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Prospective, randomized control trial To determine if oral caffeine decreases the frequency of opioid demand in children with adolescent idiopathic scoliosis after their spinal fusion surgery To compare pain scale ratings, number of requests for diazepam, average heart rate, average blood pressure, sex, age, ethnicity, post-op day of discharge, operative time, estimated intraoperative blood loss, remittance post-surgery, length of hospital stay, and segments fused during spinal fusion surgery.
Detailed Description
Because these receptors are so important for modifying pain and inflammation, caffeine has been added as an adjuvant to common analgesics, such as paracetamol, ibuprofen, and aspirin in the belief that it will enhance their analgesic efficacy. Most studies used paracetamol or ibuprofen with 100 mg to 130 mg caffeine, and the most common pain conditions studied were postoperative dental pain, postpartum pain, and headache. There was a small but statistically significant benefit with caffeine used at doses of 100 mg or more, which was not dependent on the pain condition or type of analgesic. Additionally, trials have shown superior efficacy of adding caffeine to ibuprofen instead of administering ibuprofen alone for treating acute pain, reflecting that caffeine is an effective analgesic adjuvant. The addition of caffeine (≥ 100 mg) to a standard dose of commonly used analgesics provides a small but important increase in the proportion of participants who experience a good level of pain relief.
Finally, the beneficial effects of caffeine on aerobic activity and resistance training performance are well documented. Studies have shown that caffeine ingestion resulted in significantly lower levels of soreness compared with placebo (p ≤ 0.05). A further beneficial effect of sustained caffeine ingestion in the days after the exercise bout is an attenuation of delayed onset muscle soreness. Orthopaedic surgery also causes muscle injury, and patients might benefit from caffeine's effect on lowering muscle soreness. Acute caffeine administration also has been shown to demonstrate increases in alertness, contentment, motivation to work, talkativeness, and energy. It also decreases muscle twitches. All of these effects would be beneficial in the post-operative period, especially for Adolescence Idiopathic Scoliosis (AIS) patients undergoing spinal fusion surgery in the orthopaedic department at Children's Mercy Hospital.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adolescent Idiopathic Scoliosis
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
This study will be a prospective, randomized control trial and will be double-blinded, with the patient, provider, and researcher blinded to the treatment.
Masking
ParticipantCare ProviderInvestigator
Masking Description
This study will be a prospective, randomized control trial and will be double-blinded, with the patient, provider, and researcher blinded to the treatment.
Allocation
Randomized
Enrollment
81 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Caffeine arm
Arm Type
Active Comparator
Arm Description
Experimental Group: patient group (n = 34) receiving a 100 mg dose of caffeine (1/2 of a 200mg tablet to be taken whole or crushed), taken twice daily. This will be an adjuvant to their standard pain control.
Arm Title
Placebo arm
Arm Type
Placebo Comparator
Arm Description
Control group: patient group (n = 34) receiving placebo compounded to look similar to the caffeine treatment, taken twice daily. This will be an adjuvant to their standard pain control.
Intervention Type
Drug
Intervention Name(s)
Caffeine Tablet
Other Intervention Name(s)
Caffeine
Intervention Description
Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Blank
Intervention Description
Placebo, empty opaque dark blue blank capsule, taken twice daily. This will be an adjuvant to their standard pain control.
Primary Outcome Measure Information:
Title
Total number of demands for oral opioids from transition off PCA until discharge from hospital
Description
Documented opioid use
Time Frame
For hospital stay up to 7 days
Secondary Outcome Measure Information:
Title
Verbal analog pain scale ratings
Description
Utilizing Verbal Analog Scale 0-10, 0 being no pain and 10 being severe pain
Time Frame
For hospital stay up to 7 days
Title
Average heart rate during hospital stay
Description
Documented heart rates which are then averaged over 24 hours
Time Frame
For hospital stay up to 7 days
Title
Average systolic blood pressure during hospital stay
Description
Documented systolic blood pressures which are then averaged over 24 hours
Time Frame
For hospital stay up to 7 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
must meet criteria for surgical correction of scoliosis
must be able to swallow pills
must have English as a primary language
must possess mental capacity to understand purpose of the study
patient must carry diagnosis of adolescent idiopathic scoliosis
surgery must be performed via posterior approach
operation performed by either Dr. John T. Anderson or Dr. Richard M. Schwend
post-surgical AIS patients from June 2019-June 2024
the patient must be between the ages of 12 and 17 years old
the patient and one of their biological parents or guardian(s) must give consent for patient to be included in this study
Exclusion Criteria:
obesity, as defined by a BMI at or above the 95th percentile
weight below 40 kg
any orthopedic diagnosis other than AIS
revision spine surgery
anterior or combined approach
admission to PICU post-op
use of Oxycodone post-op
allergies to ibuprofen, caffeine, codeine, or diazepam
history of renal disease
history of a coagulation disorder
history of cardiac dysrhythmia or open heart surgery
history of Chronic Pain Syndrome or Complex Regional Pain Syndrome
current use of oral central nervous system stimulant (e.g. methylphenidate)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anne S Stuedemann, APN, MSN
Phone
816-234-3693
Email
astuedemann@cmh.edu
First Name & Middle Initial & Last Name or Official Title & Degree
JULIA LEAMON, MSN, RN
Phone
816-460-1036
Email
jleamon@cmh.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne S Stuedemann, APN, MSN
Organizational Affiliation
CHILDREN'S MERCY HOSPITALS & CLINICS
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children'S Mercy Hospitals & Clinic
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ANNE STUEDEMANN, APN, MSN
Phone
816-234-3693
Email
astuedemann@cmh.edu
First Name & Middle Initial & Last Name & Degree
JULIA LEAMON, MSN, RN
Phone
816-460-1036
Email
jleamon@cmh.edu
First Name & Middle Initial & Last Name & Degree
RICHARD M SCHWEND, MD
First Name & Middle Initial & Last Name & Degree
JOHN T ANDERSON, MD
First Name & Middle Initial & Last Name & Degree
NICOLETTE SADDLER, MSN
First Name & Middle Initial & Last Name & Degree
MICHON HUSTON, PA-C
First Name & Middle Initial & Last Name & Degree
ARMAND MOREL, MD
First Name & Middle Initial & Last Name & Degree
ASHLEY SHERMAN, MS
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
only the research team will have access to study results. No IPD will be shared with anyone outside of the research team.
Learn more about this trial
Oral Caffeine Use for Pain Management in AIS Patients After Spinal Fusion
We'll reach out to this number within 24 hrs